Essential Drugs Monitor No. 031 (2002)
(2002; 72 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentEssential Drugs Monitor
Ouvrir ce répertoire et afficher son contenuEditorial
Ouvrir ce répertoire et afficher son contenuConflict of Interest
Afficher le documentLetter from the Editor
Fermer ce répertoireNews Desk
Afficher le documentCalls for stronger consumer voice at conference on medicines and media
Afficher le documentRegulating drug promotion in Europe: meeting debates way forward
Afficher le documentAlliance protects rights to genetic resources
Afficher le documentRussia acts to curb counterfeits
Afficher le documentISDB defines genuinely innovative drugs
Afficher le documentDelhi: commitment to continuing pharmacy education
Afficher le documentDrug companies employ many more staff for marketing than R&D
Afficher le documentWorld Consumer Rights Day
Afficher le documentUS groups criticise magazine's special issue on health
Afficher le documentAustralia reports on a decade of quality use
Afficher le documentAdverse reactions to drugs increase
Afficher le documentLearning how to get RUD messages across to communities
Afficher le documentUN initiative evaluates HIV medicines
Afficher le documentConference promotes regional collaboration in SAARC countries
Afficher le documentTackling antimicrobial resistance
Afficher le documentStudy on research and development costs questioned
Afficher le documentWHO at work in Afghanistan
Afficher le documentNetscan, Meetings & Courses
Ouvrir ce répertoire et afficher son contenuResearch
Ouvrir ce répertoire et afficher son contenuDrug Promotion
Ouvrir ce répertoire et afficher son contenuNational Drug Policy
Ouvrir ce répertoire et afficher son contenuAccess
Ouvrir ce répertoire et afficher son contenuRational Use
Ouvrir ce répertoire et afficher son contenuAccess
 

UN initiative evaluates HIV medicines

A NEW effort to assess the quality of HIV medicines could make treatment services more accessible to poor countries. WHO has evaluated several HIV-related medicines, and on 20 March 2002 published the first list of products which were found to meet WHO recommended standards. The project's initial phase includes 40 products from eight branded and generic manufacturers. Managed by WHO, the initiative also involves UNICEF, and the UNAIDS Secretariat, with support from the UN Population Fund and the World Bank.

A dynamic process

The pilot project evaluates pharmaceutical products according to WHO's recommended standards of quality, and for compliance to Good Manufacturing Practices. It is just the beginning of an ongoing process that will keep adding products and suppliers to its list, as and when they are found to meet the set standards. The list is available on the WHO web site: http://www.who.int/medicines and on those of the collaborating agencies. So far eight companies have been evaluated, with another 13 suppliers and 100 products currently under review.


The new UN initiative on HIV medicines aims to make treatment more accessible for patients such as this at an AIDS reception centre in Brazil

Photo: WHO/PAHO/A. Waak

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013